Influence of medicinal products of various pharmacological groups on hemostasis system indicators
DOI:
https://doi.org/10.15587/2519-8025.2026.363088Keywords:
laboratory parameters, drugs, hemostasis, fibrinolysis, platelets, coagulation, D-dimer, antithrombin IIIAbstract
Objective. To evaluate the effect of drugs from different pharmacological groups on the hemostasis and fibrinolysis systems and to determine the most significant laboratory changes during pharmacotherapy.
Materials and methods. The study was conducted at a municipal clinical hospital and included 44 patients aged over 52 years. Patients were divided into three groups depending on the therapy received: cardiovascular drugs, antibiotics, and drugs for musculoskeletal disorders. Parameters of platelet, coagulation hemostasis, and fibrinolysis were assessed using a hemocoagulograph.
Results. All studied drug groups affected the platelet component of hemostasis, leading to decreased platelet aggregation and shortened clotting time. The most pronounced changes in coagulation parameters were observed in patients receiving cardiovascular drugs, including reduced activated partial thromboplastin time and prothrombin time. After discontinuation, partial normalization of parameters was observed. The impact on fibrinolysis was minimal in most groups; however, long-term use of cardiovascular drugs showed a tendency toward hypercoagulation, confirmed by increased D-dimer and antithrombin III levels.
Conclusions. Drugs from various pharmacological groups significantly affect hemostasis, primarily the platelet component, while cardiovascular drugs also influence coagulation and fibrinolysis. These findings highlight the importance of considering drug effects when interpreting laboratory results to avoid diagnostic errors
References
- Ryskina, K., Jessica Dine, C., Gitelman, Y., Leri, D., Patel, M., Kurtzman, G. et al. (2018). Effect of Social Comparison Feedback on Laboratory Test Ordering for Hospitalized Patients: A Randomized Controlled Trial. Journal of General Internal Medicine, 33 (10), 1639–1645. https://doi.org/10.1007/s11606-018-4482-y
- Santos, S. L., Borges, R. N., Barros, K. B. (2018). Drugs that interfere with the results of laboratory tests: an integrative review of the literature. Revista Brasileira de Análises Clínicas, 50 (2). https://doi.org/10.21877/2448-3877.201800581
- Schroeder, S. A. (2013). Can Physicians Change Their Laboratory Test Ordering Behavior? JAMA Internal Medicine, 173 (17), 1655–1656. https://doi.org/10.1001/jamainternmed.2013.7495
- van Balveren, J. A., Verboeket-van de Venne, W. P. H. G., Erdem-Eraslan, L., de Graaf, A. J., Loot, A. E., Musson, R. E. A. et al. (2018). Impact of interactions between drugs and laboratory test results on diagnostic test interpretation – a systematic review. Clinical Chemistry and Laboratory Medicine (CCLM), 56 (12), 2004–2009. https://doi.org/10.1515/cclm-2018-0900
- Smith, M. P., Bluth, M. H. (2016). Common Interferences in Drug Testing. Clinics in Laboratory Medicine, 36 (4), 663–671. https://doi.org/10.1016/j.cll.2016.07.006
- Wen, Q., Liu, R., Zhang, P. (2021). Clinical connectivity map for drug repurposing: using laboratory results to bridge drugs and diseases. BMC Medical Informatics and Decision Making, 21 (S8). https://doi.org/10.1186/s12911-021-01617-4
- Connors, J. M. (2018). Testing and monitoring direct oral anticoagulants. Blood, 132 (19), 2009–2015. https://doi.org/10.1182/blood-2018-04-791541
- Nikolac, N., Šupak Smolčić, V., Šimundić, A.-M., Ćelap, I. (2013). Croatian Society of Medical Biochemistry and Laboratory Medicine: national recommendations for venous blood sampling. Biochemia Medica, 23 (3), 242–254. https://doi.org/10.11613/bm.2013.031
- Plebani, M., Scott, S., Simundic, A.-M., Cornes, M., Padoan, A., Cadamuro, J. et al. (2025). New insights in preanalytical quality. Clinical Chemistry and Laboratory Medicine (CCLM), 63 (9), 1682–1692. https://doi.org/10.1515/cclm-2025-0478
- Yao, H., Rayburn, E. R., Shi, Q., Gao, L., Hu, W., Li, H. (2016). FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels. Critical Reviews in Clinical Laboratory Sciences, 54 (1), 1–17. https://doi.org/10.1080/10408363.2016.1191425
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Rymma Yeromenko, Maryna Ostapets, Olena Dolzhykova, Igor Seniuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons Attribution 4.0 International License copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
3. Authors have the right to store the final accepted version of the article in an institutional, thematic, or any other repository to ensure visibility and accessibility.
